Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Supernus Pharm
(NQ:
SUPN
)
29.10
-0.06 (-0.21%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
625,388
Open
29.32
Bid (Size)
29.06 (4)
Ask (Size)
29.10 (26)
Prev. Close
29.16
Today's Range
28.70 - 29.32
52wk Range
21.99 - 35.44
Shares Outstanding
53,145,884
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
May 09, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
SUPN Stock Earnings: Supernus Pharmaceuticals Misses Revenue for Q1 2024
May 08, 2024
SUPN stock results show that Supernus Pharmaceuticals missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Performance
YTD
+4.94%
+4.94%
1 Month
+0.34%
+0.34%
3 Month
+2.39%
+2.39%
6 Month
+6.09%
+6.09%
1 Year
-13.37%
-13.37%
More News
Read More
Supernus Announces First Quarter 2024 Financial Results
May 08, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
May 02, 2024
From
Glancy Prongay & Murray LLP
Via
Business Wire
Recap: Supernus Pharmaceuticals Q4 Earnings
February 27, 2024
Via
Benzinga
Earnings Scheduled For February 27, 2024
February 27, 2024
Via
Benzinga
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
May 01, 2024
From
Law Offices of Howard G. Smith
Via
Business Wire
Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story
May 01, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
The Law Offices of Frank R. Cruz Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
April 29, 2024
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Supernus Pharmaceuticals: Q3 Earnings Insights
November 08, 2023
Via
Benzinga
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
April 24, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's Disease
April 08, 2024
Via
Benzinga
Exposures
Product Safety
12 Health Care Stocks Moving In Monday's Pre-Market Session
April 08, 2024
Via
Benzinga
Supernus Provides Regulatory Update for SPN-830
April 08, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Biotechnology And Healthcare, A Bit Of A Lull
March 25, 2024
Via
Talk Markets
Supernus to Participate in Two Upcoming Investor Conferences
March 06, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
February 28, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Announces Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024
February 13, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent
February 05, 2024
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Mind-Bending Growth: 3 Psychedelic Stocks With Trippy Potential
December 14, 2023
Via
InvestorPlace
Botox And Similar Injections Have Associated Risks: Consumer Group Pushes for Stronger Warnings
December 12, 2023
Via
Benzinga
Exposures
Product Safety
Supernus Announces Third Quarter 2023 Financial Results
November 08, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Earnings Scheduled For November 8, 2023
November 08, 2023
Via
Benzinga
Supernus to Participate in the Jefferies London Healthcare Conference
November 07, 2023
From
Supernus Pharmaceuticals, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.